Frazier Life Sciences Management, L.P. — 13F Holdings & Portfolio

CIK 1892134 · latest 13F-HR filed 2026-08-14

Frazier Life Sciences Management, L.P. manages $4.59B in 13F-reported U.S. long-equity assets across 41 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are MIRM (19.58%), NAMS (13.35%), ERAS (9.96%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 6 new positions and exited 3; 27 existing positions rose in reported value and 5 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$4.59B

Long-equity book

Holdings
41

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+6 / −3 / ↑27 / ↓5

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 73.6%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Assets Under Management
$6.97B
Discretionary
$6.97B
Employees
64
Accounts
8
Address
1001 PAGE MILL ROAD
BUILDING 4, SUITE 200B
PALO ALTO, CA 94304
Phone
(650) 325-5156
Name Title / Status Ownership Type
BRUSH, JAMES ControlGENERAL PARTNER & PORTFOLIO MANAGER
since Nov 2021
Less than 5%Individual
CHA, ALBERT, (NMN) ControlMANAGING PARTNER
since Nov 2021
Less than 5%Individual
EMPEY, GORDON ControlCHIEF OPERATING OFFICER
since Mar 2025
Less than 5%Individual
ESTES, DANIEL ControlGENERAL PARTNER
since Nov 2021
Less than 5%Individual
FRAZIER LIFE SCIENCES MANAGEMENT, L.L.C. ControlGENERAL PARTNER
since Nov 2021
Less than 5%Domestic Entity
GALENA HOLDINGS INC ControlLIMITED PARTNER
since Nov 2021
50–75%Domestic Entity
HERON, PATRICK, JAMES ControlMANAGING PARTNER
since Nov 2021
Less than 5%Individual
MARTIN, JENNIFER, J ControlCHIEF FINANCIAL OFFICER
since Jan 2026
Less than 5%Individual
TOPPER FAMILY INC ControlLIMITED PARTNER
since Nov 2021
50–75%Domestic Entity
TOPPER, JAMES, NEWMAN ControlMANAGING PARTNER
since Nov 2021
Less than 5%Individual
ONTIVEROS, DANIEL, MCHIEF COMPLIANCE OFFICER
since Jan 2026
Less than 5%Individual
HERON, PATRICK, JAMES Control
Indirect owner via GALENA HOLDINGS INC
MEMBER
since Jan 2021
75% or moreIndividual
TOPPER, JAMES, NEWMAN Control
Indirect owner via TOPPER FAMILY INC
MEMBER
since Jan 2021
75% or moreIndividual
Ownership & leadership changes · 2 filings with changes since Nov 18, 2021

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Jan 29, 2026 filing
  • No longer listedBAILEY, STEVE, RAY · CHIEF FINANCIAL OFFICER & CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Nov 2021
  • AddedMARTIN, JENNIFER, J · CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • AddedONTIVEROS, DANIEL, M · CHIEF COMPLIANCE OFFICER · Less than 5%
Mar 31, 2025 filing
  • No longer listedGALENA HOLDINGS, LLC · LIMITED PARTNER · 50–75% · control person · listed since Nov 2021
  • No longer listedHERON, PATRICK, JAMES · MEMBER · 75% or more · indirect via GALENA HOLDINGS, LLC · control person · listed since Jan 2021
  • No longer listedTOPPER FAMILY, LLC · LIMITED PARTNER · 50–75% · control person · listed since Nov 2021
  • No longer listedTOPPER, JAMES, NEWMAN · MEMBER · 75% or more · indirect via TOPPER FAMILY, LLC · control person · listed since Jan 2021
  • AddedEMPEY, GORDON · CHIEF OPERATING OFFICER · Less than 5% · control person
  • AddedGALENA HOLDINGS INC · LIMITED PARTNER · 50–75% · control person
  • AddedHERON, PATRICK, JAMES · MEMBER · 75% or more · indirect via GALENA HOLDINGS INC · control person
  • AddedTOPPER FAMILY INC · LIMITED PARTNER · 50–75% · control person
  • AddedTOPPER, JAMES, NEWMAN · MEMBER · 75% or more · indirect via TOPPER FAMILY INC · control person
Nov 18, 2021 filing (earliest on record)
  • ListedBAILEY, STEVE, RAY · CHIEF FINANCIAL OFFICER & CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ListedBRUSH, JAMES · GENERAL PARTNER & PORTFOLIO MANAGER · Less than 5% · control person
  • ListedCHA, ALBERT, (NMN) · MANAGING PARTNER · Less than 5% · control person
  • ListedESTES, DANIEL · GENERAL PARTNER · Less than 5% · control person
  • ListedFRAZIER LIFE SCIENCES MANAGEMENT, L.L.C. · GENERAL PARTNER · Less than 5% · control person
  • ListedGALENA HOLDINGS, LLC · LIMITED PARTNER · 50–75% · control person
  • ListedHERON, PATRICK, JAMES · MANAGING PARTNER · Less than 5% · control person
  • ListedHERON, PATRICK, JAMES · MEMBER · 75% or more · indirect via GALENA HOLDINGS, LLC · control person
  • ListedTOPPER FAMILY, LLC · LIMITED PARTNER · 50–75% · control person
  • ListedTOPPER, JAMES, NEWMAN · MANAGING PARTNER · Less than 5% · control person
  • ListedTOPPER, JAMES, NEWMAN · MEMBER · 75% or more · indirect via TOPPER FAMILY, LLC · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Frazier Life Sciences Management, L.P. Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 MIRUM PHARMACEUTICALS INC MIRM 604749101 $899.1M 19.58% 7,679,684 SH
2 NEWAMSTERDAM PHARMA COMPANY NAMS N62509109 $613.0M 13.35% 18,088,902 SH
3 ERASCA INC ERAS 29479A108 $457.5M 9.96% 24,975,188 SH
4 MBX BIOSCIENCES INC MBX 55287L101 $367.2M 8.00% 6,652,013 SH
5 ARCUTIS BIOTHERAPEUTICS INC ARQT 03969K108 $258.9M 5.64% 9,874,511 SH
6 TREVI THERAPEUTICS INC TRVI 89532M101 $185.4M 4.04% 9,939,447 SH
7 KRYSTAL BIOTECH INC KRYS 501147102 $178.9M 3.90% 481,307 SH
8 MAZE THERAPEUTICS INC MAZE 578784100 $150.2M 3.27% 5,032,915 SH
9 PHATHOM PHARMACEUTICALS INC PHAT 71722W107 $135.3M 2.95% 12,466,489 SH
10 PALVELLA THERAPEUTICS INC NE PVLA 697947109 $134.8M 2.94% 882,400 SH
11 BRIDGEBIO PHARMA INC BBIO 10806X102 $115.3M 2.51% 1,548,139 SH
12 DISC MEDICINE INC IRON 254604101 $99.1M 2.16% 1,354,852 SH
13 CYTOKINETICS INC CYTK 23282W605 $98.8M 2.15% 1,159,879 SH
14 DYNE THERAPEUTICS INC DYN 26818M108 $70.0M 1.53% 3,153,082 SH
15 ASCENDIS PHARMA A/S ASND 04351P101 $60.1M 1.31% 225,155 SH
16 SAVARA INC SVRA 805111101 $59.9M 1.30% 9,720,852 SH
17 PARABILIS MEDICINES INC PBLS 698955101 $52.6M 1.14% 1,920,805 SH
18 AURA BIOSCIENCES INC AURA 05153U107 $50.4M 1.10% 7,100,000 SH
19 ACHIEVE LIFE SCIENCE INC QUIT 004468500 $49.7M 1.08% 7,614,836 SH
20 VOR BIOPHARMA INC VOR 929033207 $46.8M 1.02% 2,543,939 SH
21 ALLOGENE THERAPEUTICS INC ALLO 019770106 $46.7M 1.02% 22,446,668 SH
22 TARSUS PHARMACEUTICALS INC TARS 87650L103 $45.9M 1.00% 728,644 SH
23 BIOCRYST PHARMACEUTICALS INC BCRX 09058V103 $40.1M 0.87% 4,009,240 SH
24 ALKERMES PLC ALKS G01767105 $36.7M 0.80% 700,647 SH
25 ACADIA PHARMACEUTICALS INC ACAD 004225108 $36.4M 0.79% 1,438,198 SH
26 ZAI LAB LTD ZLAB 98887Q104 $36.1M 0.79% 1,902,320 SH
27 MANNKIND CORP MNKD 56400P706 $28.1M 0.61% 6,600,000 SH
28 DESIGN THERAPEUTICS INC DSGN 25056L103 $26.2M 0.57% 1,809,854 SH
29 ACLARIS THERAPEUTICS INC ACRS 00461U105 $26.1M 0.57% 4,925,374 SH
30 SHATTUCK LABS INC STTK 82024L103 $26.0M 0.57% 3,750,000 SH
31 KAILERA THERAPEUTICS INC KLRA 482931102 $24.2M 0.53% 1,100,000 SH
32 MONTE ROSA THERAPEUTICS INC GLUE 61225M102 $24.2M 0.53% 1,000,000 SH
33 LEXEO THERAPEUTICS INC LXEO 52886X107 $22.5M 0.49% 4,824,725 SH
34 RELAY THERAPEUTICS INC RLAY 75943R102 $19.0M 0.41% 1,015,693 SH
35 EVOLUS INC EOLS 30052C107 $18.3M 0.40% 2,630,665 SH
36 IMMUNOCORE HLDGS PLC IMCR 45258D105 $15.4M 0.34% 484,782 SH
37 VALNEVA SE VALN 92025Y103 $12.0M 0.26% 2,291,666 SH
38 NEWAMSTERDAM PHARMA COMPANY NAMSW N62509117 $10.7M 0.23% 500,333 SH
39 AUTOLUS THERAPEUTICS LTD AUTL 05280R100 $7.1M 0.15% 4,447,910 SH
40 XILIO THERAPEUTICS INC XLO 98422T209 $4.0M 0.09% 422,505 SH
41 IBIO INC IBIO 451033708 $3.4M 0.07% 1,953,467 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $4.59B 41 0001892134-26-000003
2026-03-31 2026-05-15 $3.89B 38 0001892134-26-000002
2025-12-31 2026-02-13 $3.72B 40 0001892134-26-000001
2025-09-30 2025-11-14 $3.34B 47 0001892134-25-000012
Filer Information
Address
1001 PAGE MILL ROAD
BUILDING 4, SUITE 200B
PALO ALTO, CA 94304
Phone
(650) 325-5156
Filing Manager
Frazier Life Sciences Management, L.P.
PALO ALTO, CA
Signatory
Jennifer Martin
Chief Financial Officer